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Abstract: Chronic obstructive pulmonary disease (COPD) is characterized by airflow 
obstruction that is not fully reversible; symptoms include chronic cough, sputum production, 
and dyspnea with exertion. An estimated 50% of the 24 million adults in the USA who have 
COPD are thought to be misdiagnosed or undiagnosed. Factors contributing to this include a 
low awareness of COPD and the initial symptoms of the disease among the general population, 
acceptance of these symptoms as a consequence of aging or smoking, some symptomatic simi-
larity to asthma, and failure of health care personnel to use spirometry for diagnosis. Increased 
familiarization with COPD diagnosis and treatment guidelines, and proactive identification 
of patients with increased risk of developing COPD through occupational, environmental, or 
lifestyle exposures, will assist in a timely, accurate diagnosis and effective treatment, which 
will consequently improve patient outcomes. This review addresses the issues surrounding the 
diagnosis and misdiagnosis of COPD, their consequences, and how COPD can be better man-
aged within primary care, including consideration of COPD care in patient-centered medical 
home and chronic care models.
Keywords: primary care, undiagnosed, misdiagnosed, chronic care model, patient-centered 
medical home
Introduction: definition of COPD, disease  
impact on patients, and epidemiology
Chronic obstructive pulmonary disease (COPD), which is characterized by partially 
reversible airflow obstruction, is primarily caused by exposure to cigarette smoke 
and other occupational and environmental pollutants;1 the widely used definitions 
of COPD are shown in Table 1.2–6 The most common symptoms of COPD include 
chronic cough, abnormal sputum production, and dyspnea with exertion.7 This disease 
further impacts patients through reduced lung function and reduced quality of life 
(QoL).8–10 The reduction in lung function is progressive and leads to exercise intoler-
ance, a consequent reduction in activity as patients avoid the discomfort of breathing 
difficulties, and continued physical decline.11 As the disease advances, symptoms 
worsen, exacerbations increase in frequency and severity, and lung function is further 
compromised, causing a downward spiral of events until death eventually occurs 
 ( Figure 1). The patient’s QoL, rate of decline, frequency of exacerbations, and emer-
gency hospitalizations can all be influenced and improved by lifestyle interventions 
and pharmacologic treatment.3,4,12–14
Unfortunately, COPD is not a rare condition and an estimated 50% of the 24 million 
adults in the USA who have COPD are thought to be misdiagnosed or undiagnosed.15 International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 1 Definitions of chronic obstructive pulmonary disease
Organization Definition
American Thoracic  
Society/european  
Respiratory Society 
(ATS/eRS)2
Chronic obstructive pulmonary disease 
(COPD) is a preventable and treatable 
disease state, characterized by airflow 
limitation that is not fully reversible. The 
airflow limitation is usually progressive 
and is associated with an abnormal 
inflammatory response of the lungs, to 
noxious particles or gases, primarily 
caused by cigarette smoking. Although 
COPD affects the lungs, it also produces 
significant systemic consequences.
Canadian Thoracic  
Society (CTS)3
Chronic obstructive pulmonary disease 
(COPD) is a respiratory disorder largely 
caused by smoking, and is characterized 
by progressive, partially reversible airway 
obstruction and lung hyperinflation, 
systemic manifestations, and increasing 
frequency and severity of exacerbations.
Global Initiative for  
Chronic Obstructive  
Lung Disease (GOLD)4
COPD is a preventable and treatable 
disease with some significant extra-
pulmonary effects that may contribute 
to the severity in individual patients. Its 
pulmonary component is characterized 
by airflow limitation that is not fully 
reversible. The airflow limitation is 
usually progressive and associated with 
an abnormal inflammatory response of 
the lung to noxious particles or gases.
National Institute for  
Health and Clinical  
excellence (NICe)5
COPD is characterized by airflow 
obstruction. The airflow obstruction is 
usually progressive, not fully reversible 
and does not change markedly 
over several months. The disease is 
predominantly caused by smoking.
world Health  
Organization (wHO)6
Chronic obstructive pulmonary disease 
(COPD) is a lung disease characterized 
by chronic obstruction of lung airflow 
that interferes with normal breathing 
and is not fully reversible.
The aim of this review is to identify the issues surrounding 
the diagnosis and misdiagnosis of COPD, their consequences, 
and to address how this situation can be better managed in 
primary care.
Methods
Medline searches (using PubMed) were carried out using 
variations and combinations of the following keywords: 
COPD, undiagnosed, underdiagnosis, prevalence, treat-
ment, patient-centered medical home (PCMH), and asthma. 
Bibliographies of articles were examined to identify further 
citations. All nonhuman studies and articles in languages 
other than English were excluded.
Barriers to COPD diagnosis and 
treatment
Primary care practitioner– and  
practice-related barriers
Lack of awareness and knowledge about COPD are major 
reasons why primary care practitioners (PCPs) and other 
health care providers may delay or incorrectly diagnose 
COPD. Results from a survey of American family physicians, 
nurse practitioners (NPs), and physician’s assistants (PAs) 
(n = 284) indicated that fewer than 50% of this test group 
reported knowledge or use of COPD diagnosis and treatment 
guidelines,16 suggesting that familiarity with diagnosis and 
treatment guidelines, and implementation of the recommen-
dations, could be more widespread.
Often, recognition of COPD does not occur until the 
disease has progressed to moderate or severe stages,17–19 
by which time patients’ symptoms have worsened; they 
have a poor QoL and a rapidly declining condition. This 
trend toward late recognition of the disease may persist in 
spite of a growing body of scientific literature on COPD 
and updated disease guidelines (Table 2).2–5 Guidelines for 
COPD diagnosis (Table 2)2–5 have been developed to help 
PCPs recognize patients with symptoms and those at risk of 
developing COPD; therefore awareness of and adherence to 
these guidelines can help in the early diagnosis of COPD.
Some degree of therapeutic nihilism may also contribute 
to COPD remaining undiagnosed or undertreated. Data from 
a test group of 284 physicians, NPs, and PAs showed that only 
15% of this group thought that treatment improved COPD 
symptoms, 13% thought longevity could be extended by 
COPD treatment, and 3% thought that it reduced exacerba-
tions or that pulmonary rehabilitation was useful.16
Obtaining an early diagnosis of COPD can be challenging 
for PCPs, as patients with mild COPD and a smoker’s cough 
may experience little impact on breathing ability and no obvi-
ous additional abnormal symptoms.20 Although smoking is 
the major cause of COPD, risk factors also include exposure 
to occupational dusts and air pollution, repeated childhood 
respiratory infections, poor nutrition, and α1-antitrypsin defi-
ciency; therefore, to focus solely on patients who smoke may 
also contribute to underdiagnosis of COPD. Individuals who 
are nonsmokers, but who are regularly exposed to secondhand 
smoke should also be considered at risk of COPD. A study 
by Bednarek et al21 indicates the importance of considering 
a diagnosis of COPD for nonsmokers and smokers alike, as 
detection of COPD in this study would have been reduced by 
26% if a “smokers only” criterion had been applied.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Figure 1 Disease course of chronic obstructive pulmonary disease.
Notes: The decline in forced expiratory volume in 1 second (Fev1) graph is adapted from Fletcher and Peto, 1977.9 Reproduced from “The natural history of chronic airflow 
obstruction,” British Medical Journal, C Fletcher, R Peto, vol 1, 1645–1648, copyright 1977 with permission from BMJ Publishing Group Ltd. aRefers to an inhaled occupational/
environmental toxin. 
Abbreviation: α1AHD, α1-antitrypsin deficiency.
Failure to use appropriate diagnostic tools could further 
contribute to under- or misdiagnosis.22,23 Despite spirometry 
being a vital tool to establish a diagnosis of COPD, it is widely 
underutilized, even if available in a medical practice.24,25 
A survey of 943 PCPs found that, although 64% of practices 
had access to spirometry, only 34% regularly used it.26 This 
situation does not appear to improve when the patient’s 
disease state is severe enough to warrant hospitalization. 
A retrospective review of 553 patients, hospitalized with 
respiratory failure or undergoing ventilator support, with a 
follow-up period of up to 8 years, found that only 31% of 
these patients had their diagnosis confirmed by spirometry, 
despite having a clinical diagnosis of COPD.27 To address 
these deficiencies, adequate training of PCPs and their 
practice staff in spirometry use and data interpretation is 
warranted.25,28
Diagnosis of COPD can also be hampered by diagnostic 
confusion between asthma and COPD.29 When patients 
present with cough, shortness of breath, and diminished 
exercise tolerance, there is a bias toward diagnosing 
asthma, particularly in women.30 In a study of 597 patients, 
  Tinkelman et al29 found misdiagnosis of asthma and COPD 
to be common (approximately 40% previously diagnosed 
with asthma had COPD). Financial factors may also influence 
the bias toward asthma diagnosis because, in the USA, there 
is often a “pay for performance” incentive for PCP diagno-
sis of asthma but there is not for COPD. This is in contrast 
with the situation in the UK, where incentives have been 
introduced to promote and improve diagnosis, management, 
and quality of care for patients with COPD and asthma.31,32 
Early indications are that the introduction of these incen-
tive programs is leading to improved quality of care, and 
that there has been an increase in the use of spirometry and 
subsequent diagnosis of COPD in the UK.32,33 In the instance 
of misdiagnosis of COPD as asthma, patients receive treat-
ment that is incorrect, which consequently fails to address 
their symptoms adequately.31 This is highlighted by a study 
of 328 patients with assumed asthma that found that 34% of 
the patients, in fact, had COPD.34
Patient-related barriers
It is important to recognize that patients also display a lack of 
awareness of COPD: failing to identify symptoms at the start 
of disease, accepting breathlessness and reduced exercise 
tolerance as part of normal aging, or attributing cough and 
sputum to their smoking habit. Unconsciously, such patients International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Comparison of guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease
Content ATS/ERS GOLD NICE CTS
Pages 222 113 54 28
Diagnosis/Disease staging    
Risk factors   
Natural history  
Pathology, pathogenesis, and pathophysiology   
How to test for COPD   
Stable COPD management    
Smoking cessation    
Pharmacotherapy    
Pulmonary rehabilitation    
Long-term O2    
Nutrition   
Surgery   
Sleep 
Air travel  
exacerbation    
Palliative care   
Integrated disease management   
Separate patient guide (80 pages) Answers series 
of questions
Patient education   
Translating guideline in primary care  8 page summary 
for primary care3
Follow-ups and monitoring    
Case scenarios 
Abbreviations: ATS/eRS, American Thoracic Society/european Respiratory Society; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NICe, National 
Institute for Health and Clinical excellence; CTS, Canadian Thoracic Society; COPD, chronic obstructive pulmonary disease.
adapt their lifestyle to compensate for their deteriorating 
health, until they have progressed to a stage where they have 
substantial and irreversible loss of lung function, and the 
impact is so severe that patients consider seeking medical 
opinion and intervention.35,36
Evidence from the literature suggests that early diagnosis 
and appropriate early treatment are beneficial for patients in 
terms of reduction of symptoms and improvement in QoL.37,38 
For example, smoking cessation, which is the most effective 
intervention for improving disease course and survival in the 
early stages of COPD, can be encouraged and appropriate 
therapies started while the patient still has relatively intact 
lungs.38–40 However, this therapeutic goal may prove elusive, 
as patients also avoid discussing their COPD symptoms with 
a PCP because they harbor guilt about their smoking history.41 
Such patient concerns can be alleviated by careful discus-
sion to increase their knowledge base, providing support in 
smoking cessation, and giving priority to COPD treatment, 
regardless of smoking status,42 similar to the unbiased, proac-
tive treatment given to patients with cardiovascular disease, 
irrespective of their dietary habits.43 When PCPs take this 
type of positive action to give treatment early in the course of 
disease, patient prognosis and QoL can be improved. Despite 
receiving PCP support, some patients may not be successful 
in smoking cessation programs, but COPD treatment can still 
improve the patient’s everyday QoL.17,38,44
Overall, the ongoing gap between PCP-diagnosed and 
actual COPD cases clearly illustrates that there is room for 
improvement in the level of knowledge regarding this disease 
and current treatment practices; examples in the literature 
exemplify the positive impacts of guideline implementation 
and of identifying and addressing barriers to diagnosis.45
Making changes in practice to 
improve the diagnosis and  
treatment of COPD
Diagnosis
Comprehensive guidelines have been developed by expert 
teams to aid diagnosis and treatment of patients with COPD. 
The available guidelines include those from the American 
Thoracic Society/European Thoracic Society (ATS/ERS),2 
the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD),4 the National Institute for Health and Clinical 
Excellence (NICE) in the UK,5 and the Canadian Thoracic International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Society (CTS).3 These guidelines share the same treatment 
goals but differ in the extent of detail and some recommen-
dations; the ATS/ERS and GOLD guidelines are the most 
comprehensive, while the CTS guidelines include examples 
of case management that may occur in everyday practice 
(Table 2). PCPs, PAs, and NPs should be aware of, and famil-
iar with, the COPD guidelines to ensure an early diagnosis 
and optimum management of COPD.
Another step toward improving the diagnosis of COPD 
is to have strategies in place to identify patients who may be 
at risk. There are suggested strategies in the diagnosis and 
treatment guidelines: the GOLD guidelines recommend a 
COPD evaluation for patients . 40 years old, with activity 
limitation, breathlessness, cough, and a history of smoking 
or occupational/environmental exposure,4 while a lower 
age of 35 years has been suggested by the “ABC of chronic 
obstructive pulmonary disease”46 for initiating evaluation of 
patients who have identified risks of developing COPD and 
are exhibiting preliminary symptoms.
Although the majority of patients with COPD have a 
smoking history (more than 50% of smokers will develop 
COPD),20 the respiratory symptoms of nonsmokers should 
also be evaluated for COPD diagnosis.47 If a   nonsmoking 
patient has symptoms of cough, shortness of breath, 
  diminished exercise tolerance, and expectoration, questioning 
by the PCP to establish whether occupational/environmental 
exposures could have caused the symptoms is recommended 
and, if these are ruled out, these individuals should be screened 
for α1-antitrypsin deficiency as a cause of COPD.
Currently, there are new screening initiatives under 
development and evaluation to identify patients at risk of 
developing COPD or who are already symptomatic. Such 
initiatives include a two-step lung function questionnaire48,49 
and a three-step screening strategy, which includes the follow-
ing steps: (1) assess symptoms with a questionnaire; (2) for 
those patients where Step 1 identifies a risk of COPD, a base-
line spirometry test should be performed; and (3) if baseline 
spirometry shows an abnormality, perform postbronchodilator 
spirometry. To improve the early diagnosis of patients with 
COPD, both the two-step and three-step strategies have the 
potential to be implemented in everyday practice.
Once patients at risk of COPD have been identified, 
the next step is to follow up with the tools that can confirm 
diagnosis. It is important to ensure that there are NPs, 
respiratory therapists, PCPs, or specialists who can efficiently 
and successfully champion patient spirometry, which is 
as essential to respiratory practice as electrocardiography 
is to cardiovascular investigations. As an example of how 
frequently spirometry might actually be required in diagnosis 
on a daily basis, if a PCP saw 20 patients per day, who were 
representative of the population of the National Health and 
Nutrition Examination Survey (NHANES) III, five patients 
may have respiratory symptoms and a further three patients 
may have COPD.50 With decreasing costs for baseline spirom-
etry and the possibility of reimbursement for primary care 
spirometry,51 the spirometer is becoming an affordable piece 
of equipment that will rapidly pay for itself, which will enable 
a wider uptake of this methodology.
Differentiating COPD from asthma
It is essential to differentiate COPD from asthma to ensure 
correct treatment choices and optimal patient outcomes;52 
this can be facilitated by a good understanding of the dif-
ferences between COPD and asthma. Both COPD and 
asthma are associated with inflammation and a reduced 
rate of pulmonary airflow, but they can be distinguished 
by their differing causes and inflammatory mechanisms. 
In COPD, irritants, such as smoke, activate lung epithelial 
cells to release chemotactic factors, which in turn activate 
pathways that cause elastin degradation, emphysema, mucus 
hypersecretion, and small airway fibrosis.53 In asthma, triggers 
cause immunoglobulin activation of mast cells and pathways 
leading to bronchoconstriction and inflammation.53
COPD and asthma can be differentiated by pre- and 
postbronchodilator spirometry because airway obstruction is 
only partially reversible in COPD, while it is fully reversible 
in asthma.54,55 There may also be differences between the 
symptoms and medical histories of patients with COPD and 
asthma. Often, patients with COPD are older than 35 years, 
have a history of smoking, and may suffer from a persistent, 
worsening, productive cough. In contrast, asthma can occur 
at any age but often starts in childhood or adolescence and 
is characterized by an intermittent dry cough and wheezing. 
The distinctions between COPD and asthma diagnosis and 
treatment are summarized in Tables 3 and 4.3,4,56
Correct diagnosis and treatment can be further compli-
cated in patients where asthma and COPD coexist;4 in a study 
of 597 patients with obstructive lung disease, almost 25% 
had both asthma and COPD.29 In such individuals, it is dif-
ficult to differentiate between the two diseases, so additional 
investigations such as chest X-rays may sometimes detect 
hyperinflation, flattening of diaphragm domes, and basilar 
markings in COPD, which would normally be absent in 
patients with asthma.57 Establishing the inflammatory cell 
profile in bronchoalveolar lavage fluid or sputum may also 
be used to identify COPD and asthma, as elevated levels of International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Differential diagnosis of chronic obstructive pulmonary disease and asthma
Diagnostic features COPD Asthma
Onset age Usually .35 years Typically during childhood/adolescence, but  
can be any age
Allergic hypersensitivity Family/Personal history  
rarely a factor
Usually family/personal history
Smoking history Often .20 pack-yearsa Possible but not necessarily
Symptom occurrence Chronic and persistent Intermittent; usually symptom free
Cough Persistent and productive Intermittent and nonproductive
Breathlessness Progressive and persistent Intermittent and variable
Disease course Progressive worsening  
(with exacerbations)
Stable (with exacerbations)
Nocturnal symptoms Uncommon unless severe  
disease state
Common
Cause of exacerbations Bacterial/viral respiratory  
tract infection
Allergens, cold air, or exercise
Spirometry determined GOLD  
COPD stage/asthma state
FEV1
b FEV1/FVC FEV1
b FEV1/FVC
Mild/intermittent $80% ,0.70 .80% Normalc
Moderate/mild persistent 50%–79% ,0.70 .80% Normalc
Severe/moderate persistent 30%–49% ,0.70 60%–79% Reduction #5%  
of normal
very severe/severe persistent ,30% or  
,50%  
with CRF
,0.70 ,60% Reduction .5%  
of normal
Response to bronchodilators variable, PFT does not normalize  
but may show improvement
Rapid response and PFT may greatly  
improve eg, Fev1  
improves .0.4 L after SAB
Notes: aTotal number of pack-years is calculated = (number of cigarettes smoked per day/20) × number of years smoking (O’Donnell et al, 20083); b% of predicted value; 
cnormal Fev1/FvC values for patients aged 8–19 years = 85%, 20–39 years = 80%, 40–59 years = 75%, and 60–80 years = 70%.3,4,17,20,37,46,55 
Abbreviations: GOLD, Global Initiative for Chronic Obstructive Lung Disease; COPD, chronic obstructive pulmonary disease; Fev1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; CRF, chronic respiratory failure; PFT, pulmonary function test; SAB, short-acting bronchodilator.
neutrophils are characteristic of COPD but not of asthma, and 
increased levels of eosinophils are characteristic of asthma 
but not of COPD.53,55,58
Treating COPD
Although not curable, COPD can be treated at any stage of 
the disease.3 The goals of COPD treatment are to relieve 
symptoms, prevent disease progression, improve exercise 
tolerance, improve QoL, prevent and treat exacerbations, and 
reduce mortality.4 The guidelines that provide information 
to assist diagnosis of COPD also have recommendations for 
patient treatment, which include strategies to minimize risk, 
lifestyle changes, and pharmacotherapy.2–5 The appropriate 
treatment depends on the patient, and should take into con-
sideration factors such as their current exposure to lifestyle/
environmental/occupational risk factors and the severity of 
disease (Figure 2). If the patient is a current smoker at the 
time of diagnosis, support in smoking cessation should be 
given by the PCP, because it effectively reduces the rate of 
lung function decline. Providing vaccination against influenza 
to all patients with COPD, and against pneumonia to patients 
aged $65 years and to those with forced expiratory volume 
in 1 second (FEV1) ,40% can also to help reduce the 
occurrence of exacerbations.
The pharmacologic treatment of COPD is centered 
on the use of bronchodilators (β-2 agonists and anticho-
linergics) and inhaled corticosteroids.4 Depending on the 
severity of disease, the bronchodilators may be adminis-
tered as required or as long-term maintenance therapy.4 
Combination therapy with bronchodilators and inhaled 
corticosteroids is used to achieve effective bronchodilation 
as disease severity and pulmonary obstruction increase, with 
inhaled corticosteroids added to the treatment regime when 
a severe stage of disease is reached.4,59 Patients with severe 
COPD may also have hypoxemia and/or hypercapnia, which 
can be improved by the use of supplemental oxygen; this 
treatment can also lead to improvements in the patients’ 
exercise capacity.60
These treatments are effective ways of meeting the 
goals of COPD management. A beneficial addition to phar-
macotherapy is participation by the patient in pulmonary 
rehabilitation, which is recommended for all patients with International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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Table 4 Differential treatment of chronic obstructive pulmonary 
disease and asthma
Treatment COPD Asthma
Smoking  
cessation
Recommended, as  
smoking accelerates  
decline of lung function
Recommended, as  
smoking exacerbates  
condition
Air pollution Avoid Avoid
Allergen – Avoid/Reduce
Influenza  
vaccination
Recommended Recommended
ICS3,4,56 Not first-line therapy,  
reserved for use in  
severe/very severe  
COPD in combination 
with long-acting  
bronchodilator
Preferred therapy  
for inflammation in  
persistent asthma
β-2 agonists Short-acting for  
short-term therapy at  
any disease state; long- 
acting β-2 agonists  
recommended in  
moderate and severe,  
if short-acting β-2  
agonists not effective
Recommended with  
ICS, if asthma not  
well controlled  
with ICS alone
Anticholinergics Short-acting and long- 
acting anticholinergics 
are recommended for  
moderate to severe  
COPD
Can be an option if  
β-2 agonists not well  
tolerated, but variable  
responses; not  
indicated in the  
USA for asthma
Systemic steroids Used for exacerbation 
treatment
Used in severe asthma, 
for exacerbation  
treatment
Theophylline Bronchodilators  
preferred, due to  
potential side effects  
of theophylline
Considered after  
bronchodilators and  
ICSs, due to potential  
side effects of  
theophylline
Oxygen In advanced cases of  
COPD, when oxygen  
saturation is 88% or  
lower
For exacerbation  
management
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  ICS,  inhaled 
corticosteroid.
COPD.3,4,13 A pulmonary rehabilitation program can benefit 
patients with COPD by providing education and support to 
change behaviors, such as smoking cessation, improvement 
in nutrition, and adherence to the prescribed medication 
  regimen.61   Exercise training is a central component of pul-
monary rehabilitation, which benefits patients by inducing 
changes in muscle biochemistry, resulting in improved 
muscle function.61 These changes delay the fatigue that is 
associated with lactic acidosis and enable patients to achieve 
enhanced exercise tolerance and consequential improve-
ment in QoL.61 Exercise training also reduces dyspnea and 
increases expiratory time, thereby reducing dynamic hyper-
inflation.61 In addition, a recent review observed that pul-
monary rehabilitation can increase motivation, self-efficacy 
for exercise, and functional capacity for physical activity, 
thereby enhancing activity and participation in extended 
activities of daily living.62
The patient-centered medical 
home – a chronic care model  
for COPD
Care for many patients with COPD is not optimal because it 
consists of rescue therapy during hospital visits for episodic 
exacerbations, with little or no treatment follow-up, rather 
than the recommended lifestyle change, long-term mainte-
nance pharmacotherapy, and pulmonary rehabilitation. There 
is a need to move away from the rescue treatment approach 
toward a more patient-centric care model incorporating regu-
lar planned care. The chronic care model (CCM) provides a 
solution based on high-quality care focused on the following 
components.63
1.	 Enabling patient self-management by providing educa-
tion, tools, motivation, and support to modify behaviors. 
Patients should be encouraged to be active participants 
in their medical care, tracking changes and reporting 
symptoms.
2.	 Establishing a practice team (ie, respiratory therapists, NPs, 
and PCPs), who give patients regular planned care and 
access to medical care, 24 hours a day, 7 days a week.
3.	 Implementing diagnostic and management guidelines 
that facilitate disease state management (eg, ATS/ERS, 
GOLD, NICE, or CTS) and provide continuity of care 
with referrals for comorbid conditions. The performance 
against guideline benchmarks should be assessed.
4.	 Applying population-based care and providing feedback 
to the clinical information systems (eg, registries).
Although there are limited data on the effectiveness of a 
CCM in COPD treatment, systematic reviews have shown that 
the model significantly reduces hospitalizations and the dura-
tion of emergency room visits when two or more of the above 
components are implemented.63,64 In addition to reducing 
health care utilization, application of a CCM to patients with 
COPD has also been shown to improve patients’ QoL.65
The CCM suggestions for patients with COPD are aligned 
with the tenets of the patient-centered medical home (PCMH) 
(Figure 3), the principles of which were developed jointly by 
the American Academy of Family Practice, American Col-
lege of Physicians, American Academy of Pediatrics, and 
American Osteopathic Association.66International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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• FEV1/FVC < 0.70
• FEV1 ≥ 80% predicted
• FEV1/FVC < 0.70
• 
• FEV1/FVC < 0.70
• 
• FEV1/FVC < 0.70
• FEV1 < 30% predicted
   or FEV1 < 50%
   predicted plus chronic
   respiratory failure
Active reduction of risk factor(s); influenza vaccination
Add short-acting bronchodilator (when needed)
Add regular treatment with one or more long-acting bronchodilators
(when needed); Add rehabilitation
Add inhaled glucocorticosteroids if
repeated exacerbations
Add long-term oxygen if
chronic respiratory
failure
Consider surgical
treatments
I: Mild II: Moderate III: Severe IV: Very severe
30% ≤ FEV1 < 50%
predicted 50% ≤ FEV1 < 80%
predicted
Figure 2 Therapy at progressing stages of chronic obstructive pulmonary disease.4 
Note: From the Global Strategy for Diagnosis, Management and Prevention of COPD, updated 2010 used with permission from the Global Initiative for Chronic Obstructive Lung 
Disease (GOLD), www.goldcopd.org.
Abbreviations: Fev1, forced expiratory volume in 1 second; FvC, forced vital capacity.
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diagnosis
Patient
input
Informed
COPD patient
care team
Continued and
integrated care
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• Patient screening
• Spirometry, discussion
   and examination of
   those at risk
Informed COPD patient
care team
• Support smoking
   cessation
• Explain disease course,
   how to optimize QoL
   and reduce symptoms
• Give GOLD stage
   appropriate treatment
• Demonstrate inhaler
   use
Patient input
• Describes symptoms,
   initially and throughout
   treatment
• Shares information about
   COPD and treatment with
   family
• Attends drop-in-group
• Can contact care team by
   e-mail/phone about
   changes in condition or
   concerns
Continued and integrated
care
• Flu and pneumonia vaccines
• Routine check-ups
• Rapid response from
   PCMH
• Open access schedule with
   extended hours
• Extended care team share
   patient notes electronically
• Post exacerbation follow-ups
Figure 3 Chronic obstructive pulmonary disease care in a patient-centered medical home (PCMH). 
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; QoL, quality of life; PCMH, patient-centered 
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The PCMH is a refinement of and complement to the 
CCM67 and involves a multidisciplinary team that is focused 
on maintaining wellness rather than merely reacting to acute 
illness.66 The PCMH team is led by a PCP, who guides patient 
education, is the first point-of-care contact, and oversees 
continuous care. The core principles inherent to chronic 
COPD care practiced in a PCMH include proactive diag-
nosis, informed COPD patient care team, patient input, and 
continued and   integrated care (Figure 3). Spirometry features 
prominently as part of the proactive diagnosis tenet. For 
instance, in managing a patient’s care across different settings 
over time, a patient could be referred to a pulmonary function 
laboratory should the practice not have office spirometry or 
a pulmonologist available. Sharing of medical information 
via electronic means will also provide all the relevant health 
care   providers with a patient’s pulmonary function readings 
and other results needed to develop a long-term COPD 
  management plan (eg, risk reduction measures, medication 
use, increasing physical activity) to improve whole patient 
care and long-term well-being.68
A central feature of the PCMH is to consider the patient 
and all their comorbid conditions simultaneously, rather than 
focusing on just one disease in isolation. This approach is of 
particular relevance to the care of patients with COPD, who 
often have multiple comorbidities and resulting polyphar-
macy. To facilitate care, patients receive enhanced access to 
care when needed, while ensuring against overtreatment, and 
also receive extended hours and longer consultations with 
various team members as appropriate. In addition to tradi-
tional consultations, extended care can also include telephone 
and e-mail access or involvement in a specific patient group. 
All aspects of the PCMH should be monitored for quality and 
safety, to enable continual improvements to be made.69,70
Given the lack of research within the USA on the appli-
cation and effectiveness of CCM and PCMH principles to 
COPD in the clinic, more research is needed on the clinical 
integration of evidence-based science in COPD.
Conclusion
Underdiagnosis and misdiagnosis of COPD leave patients with 
a reduced QoL and, potentially, a more rapidly progressing 
disease. In this respect, patients do not receive adequate care. 
Although guidelines and tools for the diagnosis of COPD are 
readily available, practitioner- and patient-related barriers can 
prevent an early diagnosis of this disease. Early diagnosis 
and management of COPD can improve long-term progno-
sis, giving patients the best opportunities to stop smoking, 
improve their QoL, reduce their symptoms, and reduce and 
delay both exacerbations and hospitalizations. To achieve 
earlier diagnosis and high standards of care for patients with 
COPD, improvements may be required at several levels within 
the health care system, including the utilization of patient 
care models such as the CCM and PCMH, and regular imple-
mentation of diagnosis and treatment guidelines by health 
care teams, together with provision of regular education and 
support to patients and their care providers.
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